Dabur Pharma Ltd. (NSE: DABURPHARM, BSE: 532545), India’s leading oncology player, today announced that it has recently signed an agreement with Government Pharmaceutical Organization (GPO) of Thailand for generic version of one of its key anticancer products.

Mr. Ajay Kumar Vij, CEO Dabur Pharma, said “Dabur Pharma is committed to providing high quality anticancer products at cost effective prices. The agreement with GPO has been signed for generic Docetaxel Injection at a very special price. GPO will be importing the product in Thailand and then making it available to needy patients. This agreement is to support the efforts of H. E. the Health Minister of Thailand to provide universal access to essential medicines for patients with low income by way of Compulsory Licensing. The company salutes this humanitarian initiative of the Royal Thai Government and is not looking for economic gains on this deal.”

Dabur Pharma is known to be one of the leading players in the field of oncology and is among the top generic oncology companies in various markets, including in Thailand, Philippines, Malaysia & India. Besides presence in more than 40 countries, the company has strong presence in the US with substantial market shares for Paclitaxel Injection and Irinotecan Injection.

- End -

About Dabur Pharma

Dabur Pharma Ltd. is committed to the discovery, development and marketing of drugs that fight cancer. Dedicated to its mission of making cancer therapy available to more and more people, it has been expanding ever since inception. The Company is the leader in the Indian Oncology market and it offers a complete range of products in this segment spanning across Injectables, Orals, Intermediates and APIs and is present in over 40 countries.